Serum free light chains: diagnostic and prognostic value in multiple myeloma
Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with se...
Saved in:
Published in | Clinical chemistry and laboratory medicine Vol. 47; no. 9; pp. 1101 - 1107 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
Walter de Gruyter
01.09.2009
De Gruyter |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. Methods: We measured FLC concentrations and calculated the kappa/lambda (κ/λ) FLC ratios for three groups (control, polyclonal gammopathy and MM). Results: The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for κ and λ secretors, respectively, for assessing survival. Survival was 30 months in patients with the κ/λ ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Conclusions: Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the κ/λ ratio provides prognostic information in these same patients. Clin Chem Lab Med 2009;47:1101–7. |
---|---|
AbstractList | Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. Methods: We measured FLC concentrations and calculated the kappa/lambda ( Kappa / lambda ) FLC ratios for three groups (control, polyclonal gammopathy and MM). Results: The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for Kappa and lambda secretors, respectively, for assessing survival. Survival was 30months in patients with the Kappa / lambda ratio of >57.5 and <0.04 compared to 47months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Conclusions: Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the Kappa / lambda ratio provides prognostic information in these same patients. Clin Chem Lab Med 2009; 47:1101-7. Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. We measured FLC concentrations and calculated the kappa/lambda (kappa/lambda) FLC ratios for three groups (control, polyclonal gammopathy and MM). The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for kappa and lambda secretors, respectively, for assessing survival. Survival was 30 months in patients with the kappa/lambda ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the kappa/lambda ratio provides prognostic information in these same patients. Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM. Methods: We measured FLC concentrations and calculated the kappa/lambda (κ/λ) FLC ratios for three groups (control, polyclonal gammopathy and MM). Results: The FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for κ and λ secretors, respectively, for assessing survival. Survival was 30 months in patients with the κ/λ ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011). Conclusions: Despite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the κ/λ ratio provides prognostic information in these same patients. Clin Chem Lab Med 2009;47:1101–7. BACKGROUNDMeasurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM.METHODSWe measured FLC concentrations and calculated the kappa/lambda (kappa/lambda) FLC ratios for three groups (control, polyclonal gammopathy and MM).RESULTSThe FLC ratio at a cut-off threshold of 2.0 showed higher sensitivity and specificity compared with serum electrophoresis for the diagnosis of MM. We used the median FLC ratio of >57.5 and <0.04 for kappa and lambda secretors, respectively, for assessing survival. Survival was 30 months in patients with the kappa/lambda ratio of >57.5 and <0.04 compared to 47 months in patients with the ratio <57.5 and >0.04, indicating that more abnormal serum FLC ratios are associated with poorer survival (p<0.011).CONCLUSIONSDespite the limitations of the assay, the results of our study indicate that the FLC assay in combination with serum PE has an increased sensitivity in the diagnosis of MM. Also, baseline measurement of the kappa/lambda ratio provides prognostic information in these same patients. |
Author | Nadarajan, Veerasekaran Gin Gin, Gan Nordin, Nani Sthaneshwar, Pavai Maniam, Jayaranee A.S. |
Author_xml | – sequence: 1 givenname: Pavai surname: Sthaneshwar fullname: Sthaneshwar, Pavai organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya – sequence: 2 givenname: Veerasekaran surname: Nadarajan fullname: Nadarajan, Veerasekaran organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya – sequence: 3 givenname: Jayaranee A.S. surname: Maniam fullname: Maniam, Jayaranee A.S. organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya – sequence: 4 givenname: Nani surname: Nordin fullname: Nordin, Nani organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya – sequence: 5 givenname: Gan surname: Gin Gin fullname: Gin Gin, Gan organization: Department of Pathology, University of Malaya, Kuala Lumpur, Malaya |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21964749$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19728852$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1P3DAURa2KqsC0y24rb1pWGfwZJ93RAUrLINQCm26sF-cF3DrJYCcI_j2ZMoVdF5b95KP7rs4u2er6Dgl5z9mca673F4vl2VwwVs5Fzl6RHa6kyZSUfOvvW2V5Lvg22U3pN2Nca2XekG1eGlEUWuyQ5QXGsaVNRKTBX98M1N2A79JnWnu47vo0eEehq-kq9v_GOwgjUt_RdgyDXwWk7QOGvoW35HUDIeG7zT0jV8dHl4uTbHn-9dviYJk5JdmQibyosK6qymkuC1BTS6VBlUJIJusKhCmgRFZI5go00jjOcgam0abmtQAtZ2TvKXcqdTtiGmzrk8MQoMN-TNYoXTKtBZvIT_8lc5NLqaYzI9kT6GKfUsTGrqJvIT5YzuxatF2LtmvRdhI98R82wWPVYv1Cb8xOwMcNAMlBaCJ0zqdnTvAyV0aVL4t9GvD--R_in6mcNNr-uFT2-y_Df56cHtov8hHvi5Vs |
CitedBy_id | crossref_primary_10_1007_s11899_016_0307_4 crossref_primary_10_1016_j_cca_2013_08_018 crossref_primary_10_17650_1818_8346_2020_15_3_38_50 crossref_primary_10_3109_10428194_2012_704033 crossref_primary_10_1371_journal_pone_0166841 crossref_primary_10_1515_CCLM_2010_283 crossref_primary_10_1515_CCLM_2011_019 crossref_primary_10_1007_s13631_016_0130_x crossref_primary_10_1177_0004563213518758 crossref_primary_10_1515_CCLM_2009_265 |
Cites_doi | 10.1046/j.1365-2141.1997.8672495.x 10.1093/clinchem/47.4.673 10.1046/j.1365-2141.2003.04355.x 10.1182/blood.V97.9.2900 10.1111/j.1365-2141.2008.07079.x 10.2307/2281868 10.1016/j.clinbiochem.2006.11.011 10.1007/s00277-005-1047-z 10.1182/blood.V63.2.468.468 10.1111/j.1365-2141.2004.05045.x 10.1373/49.8.1252 10.1038/leu.2008.171 10.1016/0002-9343(67)90074-5 10.1111/j.1365-2141.1990.tb07790.x 10.1373/clinchem.2008.106153 10.1038/leu.2008.307 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U 10.1182/blood-2007-01-067728 10.1016/S0140-6736(03)12457-9 10.3346/jkms.2006.21.4.639 10.1111/j.1365-2141.2007.06561.x 10.1093/clinchem/48.9.1437 10.1182/blood.V97.6.1566 10.1309/AJCPR2M4EUYNHLGM 10.1016/S0009-9120(02)00386-7 |
ContentType | Journal Article |
Copyright | 2009 INIST-CNRS |
Copyright_xml | – notice: 2009 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7T5 H94 |
DOI | 10.1515/CCLM.2009.260 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry |
EISSN | 1437-4331 |
EndPage | 1107 |
ExternalDocumentID | 10_1515_CCLM_2009_260 19728852 21964749 ark_67375_QT4_JZ71RHKD_B |
Genre | Evaluation Studies Journal Article |
GroupedDBID | --- -~0 0R~ 0~D 1CY 29B 354 36B 4.4 53G 5GY 5RE 9-L AAAEU AABBZ AAFNC AAFPC AAGVJ AAILP AALGR AAONY AAOQK AAOTM AAOWA AAPJK AAQCX AASQH AAWFC AAXCG ABAOT ABAQN ABFKT ABFQV ABIQR ABJNI ABLJU ABMIY ABPLS ABRDF ABRQL ABUBZ ABUVI ABVMU ABWLS ABXMZ ABYBW ACEFL ACGFS ACIWK ACMKP ACPMA ACPRK ACXLN ACZBO ADALX ADDWE ADEQT ADGQD ADGYE ADOZN ADUQZ AEDGQ AEGVQ AEICA AEJTT AEKEB AENEX AEQDQ AERZL AEXIE AFAUI AFBAA AFBQV AFCXV AFGDO AFGNR AFQUK AFRAH AFYRI AGBEV AGGNV AHOVO AHVWV AHXUK AIERV AIKXB AJATJ AJHHK AKXKS ALMA_UNASSIGNED_HOLDINGS ALUKF ALYBR AMAVY ASPBG ASYPN AVWKF AZFZN AZMOX BAKPI BBCWN BCIFA BSCLL BWHEM CAG CGQUA COF CS3 DA2 DBYYV DU5 EJD EMOBN F5P FSTRU HZ~ IL9 IY9 KDIRW N9A O9- OBC OBS OEB OES OHH OVD P2P PQQKQ QD8 RDG SA. SLJYH TEORI UK5 WTRAM ~Z8 .55 .GJ AAEMA AAUGY AAZFL ABPTK ACTFP AI. AIGSN DSRVY EBS EYIDJ IQODW ITC VH1 X7M ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 7T5 H94 |
ID | FETCH-LOGICAL-c430t-268bedbbbc5138a443445a4922303dba278a9e0830c8e737c1060a7f57d1d2a53 |
ISSN | 1434-6621 |
IngestDate | Fri Oct 25 09:09:34 EDT 2024 Fri Oct 25 02:58:22 EDT 2024 Thu Sep 12 18:43:50 EDT 2024 Sat Sep 28 07:55:52 EDT 2024 Sun Oct 22 16:07:28 EDT 2023 Wed Oct 30 09:48:33 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | microglobulin Immunopathology multiple myeloma Prognosis Free form serum electrophoresis Malignant hemopathy Light peptide chain Myeloma Medicine β serum free light chains Immunoglobulinopathy Lymphoproliferative syndrome Clinical biology Electrophoresis Serum Diagnosis Cancer β2-Microglobulin |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c430t-268bedbbbc5138a443445a4922303dba278a9e0830c8e737c1060a7f57d1d2a53 |
Notes | ark:/67375/QT4-JZ71RHKD-B ArticleID:cclm.2009.260 istex:F6A6197DF06313C6FC7852ABEF608A9B7E4A1159 cclm.2009.260.pdf ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
OpenAccessLink | https://edoc.hu-berlin.de/bitstream/18452/11422/1/cclm.2009.260.pdf |
PMID | 19728852 |
PQID | 67633463 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_745905520 proquest_miscellaneous_67633463 crossref_primary_10_1515_CCLM_2009_260 pubmed_primary_19728852 pascalfrancis_primary_21964749 istex_primary_ark_67375_QT4_JZ71RHKD_B |
PublicationCentury | 2000 |
PublicationDate | 2009-09-01 |
PublicationDateYYYYMMDD | 2009-09-01 |
PublicationDate_xml | – month: 09 year: 2009 text: 2009-09-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany |
PublicationTitle | Clinical chemistry and laboratory medicine |
PublicationTitleAlternate | Clin Chem Lab Med |
PublicationYear | 2009 |
Publisher | Walter de Gruyter De Gruyter |
Publisher_xml | – name: Walter de Gruyter – name: De Gruyter |
References | p_23 p_24 p_25 p_26 Katzmann JA (p_4) 2002; 48 Bataille R (p_22) 1984; 63 p_20 p_21 p_16 p_17 p_2 p_18 p_19 p_12 p_3 p_13 p_14 p_5 p_15 p_8 p_7 p_9 Bradwell AR (p_6) 2001; 47 p_10 p_11 Merlini G (p_1) 1995; 8 |
References_xml | – ident: p_23 doi: 10.1046/j.1365-2141.1997.8672495.x – volume: 47 start-page: 673 year: 2001 ident: p_6 publication-title: Clin Chem doi: 10.1093/clinchem/47.4.673 contributor: fullname: Bradwell AR – ident: p_2 doi: 10.1046/j.1365-2141.2003.04355.x – ident: p_10 doi: 10.1182/blood.V97.9.2900 – ident: p_11 doi: 10.1111/j.1365-2141.2008.07079.x – ident: p_8 doi: 10.2307/2281868 – ident: p_9 doi: 10.1016/j.clinbiochem.2006.11.011 – volume: 8 start-page: 173 year: 1995 ident: p_1 publication-title: Cancer J contributor: fullname: Merlini G – ident: p_15 doi: 10.1007/s00277-005-1047-z – volume: 63 start-page: 468 year: 1984 ident: p_22 publication-title: Blood doi: 10.1182/blood.V63.2.468.468 contributor: fullname: Bataille R – ident: p_12 doi: 10.1111/j.1365-2141.2004.05045.x – ident: p_13 doi: 10.1373/49.8.1252 – ident: p_7 doi: 10.1038/leu.2008.171 – ident: p_17 doi: 10.1016/0002-9343(67)90074-5 – ident: p_21 doi: 10.1111/j.1365-2141.1990.tb07790.x – ident: p_16 doi: 10.1373/clinchem.2008.106153 – ident: p_26 doi: 10.1038/leu.2008.307 – ident: p_18 doi: 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U – ident: p_24 doi: 10.1182/blood-2007-01-067728 – ident: p_3 doi: 10.1016/S0140-6736(03)12457-9 – ident: p_19 doi: 10.3346/jkms.2006.21.4.639 – ident: p_25 doi: 10.1111/j.1365-2141.2007.06561.x – volume: 48 start-page: 1437 year: 2002 ident: p_4 publication-title: Clin Chem doi: 10.1093/clinchem/48.9.1437 contributor: fullname: Katzmann JA – ident: p_20 doi: 10.1182/blood.V97.6.1566 – ident: p_14 doi: 10.1309/AJCPR2M4EUYNHLGM – ident: p_5 doi: 10.1016/S0009-9120(02)00386-7 |
SSID | ssj0015547 |
Score | 2.03732 |
Snippet | Background: Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell... Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim... BACKGROUNDMeasurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias.... |
SourceID | proquest crossref pubmed pascalfrancis istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1101 |
SubjectTerms | Aged Biological and medical sciences Blood Protein Electrophoresis - methods Female General aspects Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulin kappa-Chains - blood Immunoglobulin lambda-Chains - blood Immunoglobulinopathies Immunopathology Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - mortality Prognosis Sensitivity and Specificity serum electrophoresis serum free light chains Survival Analysis β2-microglobulin |
Title | Serum free light chains: diagnostic and prognostic value in multiple myeloma |
URI | https://api.istex.fr/ark:/67375/QT4-JZ71RHKD-B/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/19728852 https://search.proquest.com/docview/67633463 https://search.proquest.com/docview/745905520 |
Volume | 47 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKKgEvCMatXIYfEC9TIYntOOGtK4NqrBOXbpp4iezE0bqt6ZS2jPHrOb4kaadVAl6qNvf6-3xyjn3OZ4ReC-WB20BlV0roblRBnBLxzOvm4JxmxGfCi3U18vAgHBzSvWN23GpdLleXzOXb9PeNdSX_gypsA1x1lew_IFtfFDbAd8AXPgFh-PwrjKGjLybbeanU9rkOsnUZrx4_hig_syl0lRyrTsNyP7W8t1EKqXMJJ1fqfOrscyVaUBVMptWCcOYyjjJ6Xv76pPx3PQavZieXNmP7i_gpxvVIs8hEKU7tWOuRUiW8Os9gS03MoSjGrl5bXOkd8I96zajsAUTIVusAXgbjlYGKJhML3jPWuFLCmwotZ32t3qZjWbxkSsEv8W-08czIYfT7-0MrNxrYBQmW8L6YGMD1impRZAVyr4lqV7tuoXYAFgpMY7v3aWf3qJ6AAi-LO0lWuN-7lbsZoVl7_oo309Yd85fOrhUzQCi3K6OsD12MCzO6j-652AP3LJEeoJYqNtGdfoXwJro9dKA-RPuGW1hzCxtuYcut97hhFgZK4IZZ2DALjwtcMQs7Zj1Chx93R_1B16280U0p8ebdIIykyqSUKfNJJCgllDJBY_AlPZJJEfBIxAq8dy-NFCc89b3QEzxnPPOzQDDyGG0U00I9RZgTn-QkFyGNfMq4lIxk4AX7eQixc65IB72pWjC5sAIriQ5ModUT3ep6ndQ4gVaHA0371keJ8kxnJXKWfB3RZO8H978NPn9IdjpoawWA-oRAi89xGnfQqwqRBBpYz5ABr6eLGVwuJISG8FB4zRGcsthjLIDHeWKxbJ7aceLZ2j3P0d2mY7xAG_NyoV6CTzuXW45_fwBeP6Gg |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Walter de Gruyter |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+free+light+chains%3A+diagnostic+and+prognostic+value+in+multiple+myeloma&rft.jtitle=Clinical+chemistry+and+laboratory+medicine&rft.au=Sthaneshwar%2C+Pavai&rft.au=Nadarajan%2C+Veerasekaran&rft.au=Maniam%2C+Jayaranee+A+S&rft.au=Nordin%2C+Nani&rft.date=2009-09-01&rft.eissn=1437-4331&rft.volume=47&rft.issue=9&rft.spage=1101&rft_id=info:doi/10.1515%2FCCLM.2009.260&rft_id=info%3Apmid%2F19728852&rft.externalDocID=19728852 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon |